Pricing Log in Create free account
Saturday 17 October 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Biogen Inc. (BIIB) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 77 added · 17 removed · 102 modified
P2I1A: 18 modified
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 1, 2026 2.02 Results of operations and financial condition
8-K Jun 9, 2026 5.07 Submission of matters to a vote of security holders
8-K/A May 14, 2026 9.01 Financial statements and exhibits
8-K May 14, 2026 1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 6, 2026 2.02 Results of operations and financial condition
8-K Mar 31, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 11, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Feb 11, 2026 5.02 Departure or appointment of directors or officers; 8.01 Other events
10-K Dec 31, 2025 1: 82 added · 51 removed · 100 modified
1A: 8 added · 6 removed · 98 modified
7: 132 added · 102 removed · 112 modified
8-K Feb 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 2.02 Results of operations and financial condition
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 14, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.